Evidence map›Paper›PMID 41451372›Full record

ArticleFrontiers in pharmacology2025

Real-world data analysis of the risk of Fournier's gangrene in patients using sodium-glucose cotransporter 2 inhibitors (SGLT2i).

Moritz Hertel, Hanno Jaoulak, Max Heiland, Susanne Nahles, Robert Preissner, Saskia Preissner

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Moritz HertelDepartment Oral and Maxillofacial Surgery, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Hanno JaoulakDepartment of Nephrology and Intensive Care, St. Joseph Hospital, Berlin, Germany.
Max HeilandDepartment Oral and Maxillofacial Surgery, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Susanne NahlesDepartment Oral and Maxillofacial Surgery, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Robert PreissnerInstitute of Physiology and Science-IT, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Saskia PreissnerDepartment Oral and Maxillofacial Surgery, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The aim of the present matched cohort study was to assess if patients using sodium-glucose cotransporter 2 inhibitors (SGLT2i) show an augmented risk of Fournier's gangrene (FG) compared to subjects not using SGLT2i. Methods: Retrospective data were retrieved from the TriNetX database, whereby patients using SGLT2i and individuals not using SGLT2i were assigned to cohorts I and II, respectively. After matching for age, gender distribution, and prevalence of diabetes mellitus, human immunodeficiency virus infection, alcohol abuse, liver diseases, and use of immune suppressant, a risk analysis was carried out, and risk ratio (RR) and odds ratio (OR) were determined. The outcome was defined as diagnosis of FG. Results: Before matching, cohorts I and II accounted for 192,245 and 7,810,583 subjects. After matching, 192,245 patients (40.5% females and 59.5% males; mean age 67.5 ± 12.7 years) remained per cohort. Among the cohorts I and II, 186 and 312 individuals were diagnosed with FG. The according risks of 0.1% and 0.2% were significantly different (p > 0.001; Log-Rank test). RR and OR were 0.539 (95% CI 0.447-0.650) and 0.539 (95% CI 0.446-0.650). Conclusion: The present study found a significantly lower risk of FG in patients using SGLT2i in comparison with subjects not using SGLT2i. Due to specific limitations that come alongside with the applied study design, this result needs to be interpreted most cautiously. As the cohorts were matched for the frequency of diabetes mellitus (68.9% of the cohorts I and II) this risk factor for FG might have been mitigated among the individuals in cohort I due to the use of SGLT2i, which may in turn explain the abovementioned finding.

Indexed as

adverse drug eventsdiabetes complicationsfournier’s gangrenenecrotizing fasciitisreal-world data pharmacovigilanceSGLT2 inhibitors

Identifiers

PMID41451372
PMCPMC12728056

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.